Impact of Strut Width in Periprocedural XXXX : A Propensity-Matched Comparison Between Bioresorbable Scaffolds and the First-Generation Sirolimus-Eluting Stent.

@entity1 @entity583 @entity4375 @entity299
OBJECTIVES: This study aimed to assess the clinical impact of strut width (evaluated by abluminal strut surface area [ASSA]) on periprocedural @entity583 (PMI) and clinical outcomes in @entity1 treated with bioresorbable scaffolds ( @entity4375 ) versus first-generation sirolimus-eluting stents (SES). BACKGROUND: To date, there are no reports on the impact of ASSA on PMI and clinical outcomes. METHODS: We compared the impact of ASSA on outcomes and PMI in propensity-matched @entity1 treated with @entity4375 and SES. The primary outcome was the incidence of major adverse @entity299 (MACE), defined as the combination of all-cause mortality, follow-up @entity583 , and target vessel revascularization, at 30-days and 1-year follow-ups. The secondary endpoint was the incidence of PMI. RESULTS: After propensity-matched analysis, 499 @entity1 (147 @entity4375 @entity1 vs. 352 SES @entity1 ) were evaluated. Mean ASSA was higher in @entity1 treated with @entity4375 versus SES ( @entity4375 : 132.3    76.7 mm(2) vs. SES: 67.6    48.4 mm(2), p  <  0.001). MACE was not significantly different between groups (30-days MACE: @entity4375 : 0% vs. SES: 1.4%, p  = 0.16, and 1-year MACE: @entity4375 : 15.7% vs. SES: 11.4%, p  = 0.67). The incidence of PMI was significantly higher in the @entity4375 group ( @entity4375 :  13.1% vs. SES: 7.5%, p  = 0.05). Multivariable analyses indicated that treatment of left anterior descending artery and ASSA were independent predictors of PMI. CONCLUSIONS: @entity4375 implantation, compared with SES implantation, was associated with a higher incidence of PMI. MACE at 30 days and 1 year were not significantly different. Left anterior descending artery percutaneous coronary intervention and ASSA were independent predictors of PMI.
